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Abstract
Background: Prolonged adefovir therapy exposes to the emergence of adefovir resistant hepatitis
B virus mutants. Initial reports of the rtN236T mutation showed preserved sensitivity to
lamivudine; however, complex mutations are emerging with reduced susceptibility to lamivudine.
Case presentation: After 2 years of therapy, a cirrhotic patient developed the rtN236T and
rtA181T adefovir resistant mutations. He had been previously treated with lamivudine, developed
lamivudine resistance and, despite good compliance, had an incomplete response to adefovir.
Adefovir resistance resulted in viral breakthrough with hepatitis flare-up and liver decompensation.
Tenofovir had an excellent antiviral effect allowing sustained control of viral replication and reversal
of hepatic failure.
Conclusion: In patients with cirrhosis, adefovir resistance can lead to severe hepatitis. Tenofovir
appears to be an effective treatment of adefovir resistant mutants. Incomplete control of viral
replication with adefovir requires monitoring for viral resistance and should prompt a change in
antiviral treatment.
Background
In chronic hepatitis B, prolonged antiviral therapy with
nucleoside analogues, such as lamivudine, is often neces-
sary but may result in the emergence of escape mutants
which can be detected in as many as 70% of patients, after
4 years of therapy [1]. Adefovir dipivoxil has potent anti-
viral activity on lamivudine-resistant hepatitis B virus
(HBV) strains [2,3]; nonetheless, long term use of this
nucleotide analogue is also associated with resistance in
up to 18% of patients, after 4 years of therapy [4]. In the
few cases published thus far, adefovir-resistant HBV dis-
played the rtN236T mutation and maintained susceptibil-
ity to lamivudine in vivo [5,6]. However, new adefovir-
resistant mutations have been reported, such as the
rtA181V mutation which is closely located to the rtL180M
mutation conferring resistance to lamivudine [4]. It is
uncertain whether those new adefovir escape mutants are
susceptible to lamivudine [7] and thus drugs active on
both adefovir and lamivudine-resistant HBV strains are
needed.
We report on the case of a patient with HBV-related cir-
rhosis and lamivudine-resistant HBV who developed ade-
fovir resistance with viral breakthrough and liver failure.
The patient had both an rtN236T and a rare rtA181T
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mutation. Tenofovir fumarate was highly effective in con-
trolling viral replication and reversing clinical symptoms.
Case presentation
In 1997, a 55 year-old Vietnamese man was diagnosed
with HBV cirrhosis without hepatitis delta virus (HDV),
hepatitis C virus (HCV) or human immunodeficiency
virus (HIV) coinfections. Probably, the route of infection
was vertical transmission. Cirrhosis was confirmed by
liver biopsy and was complicated only by grade 1
oesophageal varices (Child Pugh score A5). HBe antigen
was negative, HBe antibody positive, HBV viral load
(HBV-DNA) was 7.15 log10 copies/ml (Digene hybrid cap-
ture assay) and the HBV genotype was B. Alanine ami-
notransferase (ALT) values were twice the upper limit of
normal (ULN).
In August 1998, lamivudine, 100 mg/day, was started.
Three months later, HBV-DNA was undetectable by
Digene assay and, in February 1999, by qualitative PCR
(sensitivity limit at 4 log10). Lamivudine was inadvert-
ently stopped after only 10 months of treatment, and then
started again in January 2000 when a relapse occurred
with a rising HBV-DNA to 5.75 log10 and ALT values at 3.1
ULN. The next 2 years of treatment were uneventful with
undetectable HBV-DNA by quantitative PCR (cut-off at
2.3 log10, MONITOR COBAS, Roche) and normal ALT val-
ues.
In January 2002, after 24 months of uninterrupted lami-
vudine treatment, HBV-DNA became detectable by PCR
(2.6 log10), and, in June 2002, a viral breakthrough was
documented when HBV-DNA rose to 9.2 log10 with ALT at
Virological and biochemical course before and after the emergence of adefovir resistant mutations Figure 1
Virological and biochemical course before and after the emergence of adefovir resistant mutations. LAM: lamivudine; ADV: 
adefovir dipivoxil; TDF: tenofovir disoproxil fumarate.
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2.7 ULN. The patient was asymptomatic. Sequencing of
the HBV polymerase revealed two common lamivudine
resistant mutations – rtL180M and rtM204V. Adefovir
dipivoxil, 10 mg/day, was added to the ongoing lamivu-
dine treatment. The evolution of HBV viral load is shown
in the Figure. Over the next 10 months, HBV-DNA never
fell below 5 log10. In June 2003, the HBV-DNA titer was
5.28 log10. Lamivudine was then stopped, but adefovir
was maintained; in addition, pegylated interferon α-2a
was introduced (180 µg/week). In August 2003, and after
five injections, the patient decided to stop pegylated inter-
feron administration due to poor drug tolerance: ano-
rexia, dry mouth, diarrhoea, weight loss and back pain.
Thrombopenia was also detected.
After 4 months of uninterrupted adefovir monotherapy,
HBV-DNA was still at 4.9 log10 and the same lamivudine
resistant mutations were detected without adefovir resist-
ant mutations. In September 2004, while on adefovir
monotherapy, and 15 months after having stopped lami-
vudine and 13 months after having stopped pegylated
interferon, HBV-DNA rose to 8.3 log10, ALT to 10 ULN
and aspartate aminotransferase to 7 ULN. Prothrombin
time was 78%, and total bilirubin and serum albumin
were normal. Two adefovir resistant mutations, rtA181T
and rtN236T, were detected, whereas previous lamivudine
resistant mutations, rtL180M and rtM204V, were absent.
Anti-HDV and anti-HCV antibodies detection remained
negative.
A test trial of a higher dose of adefovir (20 mg/day) was
started. One month later, HBV-DNA was at 7 log10 and
ALT levels remained unchanged. The patient's condition
deteriorated with the occurrence of oedema, ascites, jaun-
dice, mild renal insufficiency (serum creatinine 110
µmol/l) and decreased prothrombin time (47% of nor-
mal). Tenofovir fumarate was then started at a dose of 300
mg/day, while adefovir was continued for one month at
10 mg/day and then stopped. Two months later, HBV-
DNA became undetectable by PCR, prothrombin time
rose to 90% while jaundice and ascites resolved. HBV-
DNA was still undetectable by PCR after 8 months of ten-
ofovir treatment, on three separate occasions. The patient
is currently listed for liver transplantation.
Discussion
Despite good compliance, after developing lamivudine
resistance the patient did not respond to adefovir
dipivoxil treatment. Although the reasons are unclear, pri-
mary non-response to adefovir has been described in 8%
to 15% of HIV-negative [2,3] and HIV-positive [8]
patients infected with lamivudine-resistant HBV. Incom-
plete viral suppression could have contributed to the
emergence of adefovir resistant mutations. Indeed, it has
already been shown that a high viral load (>3 log10) after
6 months of lamivudine therapy predicted the emergence
of resistance [9,10]. The patient developed both rtN236T
and rtA181T mutations while under adefovir treatment
for 2 years. The rtN236T and rtA181V are well-described
adefovir resistant mutations [5,6,11], whereas the
rtA181T is very rare and has only been described in 1 out
of 22 patients with adefovir resistance, after 4 years of
treatment [4]. Viral breakthrough was associated with
severe hepatic decompensation, probably favoured by
longstanding underlying cirrhosis. Similar to lamivudine
resistance, clinicians should be aware of the possibility of
severe hepatic decompensation in cirrhotic patients devel-
oping adefovir resistance; therefore, clinicians should
implement viral resistance monitoring strategies.
Non-randomized studies suggested that tenofovir has a
more potent antiviral activity than adefovir on lamivu-
dine-resistant HBV [12], whereas in HIV-HBV patients
with primary non-response to adefovir, tenofovir is highly
effective [8]. Because of the emergence of the rtA181T
mutation (which is closely located to codon 180), confer-
ring resistance to lamivudine and closely related to
rtA181V, we chose to treat this patient with tenofovir
rather than with lamivudine. In fact, the rtA181V muta-
tion reduces the susceptibility to lamivudine 14 fold in
vitro, while in vivo lamivudine has only a limited antiviral
effect on that mutant strain [13]. Brunelle et al. [14]
reported recently decreased in vitro susceptibility to both
tenofovir and adefovir of two HBV resistant mutants
(N236T adefovir and L180M + M204V + N236T lamivu-
dine/adefovir resistant strains). A similar fold resistance
over wild-type HBV was reported for tenofovir and adefo-
vir (4.5, and 3.2 to 6.4 fold, respectively), suggesting a
marginal benefit of tenofovir over adefovir. However, one
might question the in vivo relevance of those in vitro exper-
iments. In this patient with the double rtN236T and
rtA181T mutations, the antiviral response to tenofovir
was excellent. A rapid and sustained inhibition of viral
replication, by sensitive PCR, was detected after only 2
months of treatment and resulted in an improvement in
liver function to a degree that could not be anticipated
from in vitro resistance studies. Discrepancies between in
vitro  drug susceptibility and in vivo findings could be
related to differences in pharmacodynamics between the
two drugs.
Conclusion
Adefovir resistant mutations can induce severe hepatic
decompensation in cirrhotic patients and can be preceded
by incomplete viral suppression. In these patients close
viral monitoring is mandatory. For avoiding the emer-
gence of resistant mutants, incomplete viral response to
adefovir should prompt a change in antiviral treatment.
Tenofovir appears to be an effective treatment of adefovir
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